The Cynapsus development of on-demand management of “off episodes” associated with Parkinson’s disease, was a perfect fit for the Noble research platform of discovering early-stage biotechnology companies which are generally under-followed, misunderstood and/or virtually unknown to the investment community. Noble first became aware of the Canadian-based company when its Senior Equity Research Analyst, Nathan Cali, received a call from their director of business development. “I remember the call very well, said Cali, I was impressed with how their solutions could overcome tolerability and bioavailability difficulties, and immediately wanted to dig deeper into the Cynapsus story”. When Noble initiated research coverage Cynapsus’ market capitalization was only $13.9 million.

Noble’s first large-scale introduction of Cynapsus to the investment community was at NobleCon10 which was held in mid-January, 2014; six months after initiating research coverage of Cynapsus. From that point investor awareness and interest grew exponentially with the publishing of 30 more research reports, the company presenting at two more Noble Conferences, and participating in many Noble sponsored institutional investor non deal road shows. Anthony Giovinazzo, Cynapsus CEO, views Noble as a trusted advisor that has worked tirelessly to help the company and the patients advantaged by their products. “Noble took the time to understand the unique product offering of Cynapsus and assisted us in effectively communicating our story to some of Wall Street’s most respected institutional investors. Their expertise in research, investment and merchant banking with specialty pharmaceutical companies like ours, resulted in a transformative financing for Cynapsus.”